De®ning complete sets of gene family members from diverse species provides the foundation for comparative studies. Using a bioinformatic approach, we have de®ned the entire nuclear receptor complement within the ®rst available complete sequence of a non-human vertebrate (the teleost ®sh Fugu rubripes). In contrast to the human set (48 total nuclear receptors), we found 68 nuclear receptors in the Fugu genome. All 68 Fugu receptors had a clear human homolog, thus de®ning no new nuclear receptor subgroups. A reciprocal analysis showed that each human receptor had one or more Fugu orthologs, excepting CAR (NR1I3) and LXRb (NR1H2). These 68 receptors add striking diversity to the known nuclear receptor superfamily and provide important comparators to human nuclear receptors. We have compared several pharmacologically relevant human nuclear receptors (FXR, LXRa/b, CAR, PXR, VDR and PPARa/g/d) to their Fugu orthologs. This comparison included expression analysis across ®ve Fugu tissue types. All of the Fugu receptors that were analyzed by PCR in this study were expressed, indicating that the majority of the additional Fugu receptors are likely to be functional.
INTRODUCTION
Nuclear receptors (NRs) play key roles in integrating the complexities of homeostasis and development (1) . In general, NRs function as transcriptional regulators, working in concert with co-activators and co-repressors to activate and suppress target gene expression (2, 3) . The common themes of ligand binding and cofactor interaction are re¯ected in shared structural features within the superfamily. A DNA-binding domain (DBD) targets the receptor to speci®c DNA sequences, termed hormone response elements. The C-terminal portion of the receptor contains a ligand-binding domain (LBD) which interacts directly with the hormone. Ligand-induced conformation changes within the LBD dictate the activity of the receptor within a particular cellular context.
NRs have been aggressively pursued as drug targets due to their central roles in metabolism and because of their potential for modulation by exogenous compounds. Examples of current NR drug targets include the steroid and thyroid hormone receptors (targets for multiple hormone replacement therapies and for immunomodulatory and cancer drugs), the peroxisome proliferator-activated receptors (PPARs) (targets for dyslipidemia and diabetes drugs) (4) and the liver X receptors (LXRs) and farnesoid X-activated receptor (FXR) (potential targets for treatment of atheroschlerosis and dyslipidemia, respectively) (5, 6) . Moreover, NRs such as pregnane X receptor (PXR) and constitutive androstane receptor (CAR) have been shown to be important in drug metabolism (7) . A major goal of NR target discovery is to expand the knowledge of NR structure/function in order to validate additional NR family members as tractable drug targets.
Genome sequencing has recently disclosed that there are 48 functional NRs in the complete human NR set (8±10). Approximately 30 of the human NRs are still orphan with regard to function and represent an important source of untapped drug discovery targets (11, 12) . Aside from having important implications in evolutionary studies and in studies of the biology of distinct organisms, sequencing of the nonhuman genomes can be an important source of information on the function of human target class members. For example, comparison of the NR LBD amino acid residues between species can help identify conserved structural motifs and may pinpoint key functional residues. Identi®cation of primitive receptors may also help in our understanding of the origins of ligand regulation in the superfamily, ultimately giving information regarding NR tractability. Non-human genome sequencing also identi®es new models in which to generate NR functional data. The majority of NR functional analysis data have been derived from studies in genetic models such as mice, Caenorhabditis elegans and Drosophila; additional species provide new comparators for NR studies. Finally, in the case of frequently used pharmacological models such as mouse and rat, genome sequencing will help evaluate the relevance and caveats to working with these models. For example, signi®cant differences have been observed in the LBD sequences and activation pro®les of the xenobiotic receptor PXR (NR1I2) from humans versus rodents (13) . This knowledge helped to explain the highly species-speci®c cytochrome P450 3A response of each of these species to xenobiotics (14) .
The NR superfamily of genes appears to be restricted to metazoans and, to date, complete NR sets from three metazoan genomes have been de®ned (humans, Drosophila melanogaster and C.elegans). The C.elegans NR set (>270 members) displays a high degree of duplication and divergence relative to both the Drosophila (21 members) and human sets (48 members) (8, 15) . Comparison of these gene families has provided and continues to provide valuable information regarding the origin and function of speci®c NR family members. To extend this comparative genomic analysis, we have analyzed the complete NR set from a ®sh. The genome of the teleost, ray-®nned ®sh, Fugu rubripes, represents the ®rst complete non-human vertebrate genome to become available. In this manuscript, we have de®ned the complete set of Fugu NRs and have compared them to the human NR set and found that the Fugu NR set exhibits remarkable diversity and complexity. We have focused on the Fugu receptors of particular interest to current NR drug discovery research.
MATERIALS AND METHODS

Computational identi®cation of Fugu nuclear receptor sequences
The proteome, transcriptome and genomic sequences of F.rubripes were obtained from the Fugu ftp site (http:// genome.jgi-psf.org/fugu3/fugu3.info.html) and formatted for NCBI BLAST analysis. Protein homology searches were performed using nucleotide sequences of individual members of the human NR family compared against the Fugu proteome database using BLASTX (16) . The top four hits for each query were analyzed. In the event that a Fugu protein was similar to multiple members of a NR family, percent identity was used to assign putative ortholog status. The DBDs of the 48 human nuclear receptors were aligned using T-Coffee (17) and the resulting multiple sequence alignments were used to generate hidden Markov models (18, 19) . HMMer was then used to search the Fugu database for hits to DBD HMM. Seventy-four hits were obtained above an e value cut-off of 0.001. In another HMMer search, a hidden Markov model of the LBDs of nuclear receptors identi®ed 73 putative nuclear receptors from the Fugu database. Most of the hits corroborated the BLAST results. The hits from the BLAST and HMMer searches were combined resulting in 85 putative nuclear receptors. To rule out any redundant peptides, the sequence set was further re®ned using nrdb95.pl (20) . This resulted in a ®nal set of 74 putative nuclear receptors. This set contains full-length LBDs.
Based on sequence alignment, several pairs of Fugu identi®ers were combined to make complete LBDs: liver receptor homolog 1 (LRH-1) (fr006605 + fr083170), LRH-1 (fr057871 + fr070767), retinoic acid receptor (RAR) (fr079596+ fr088133), retinoid X receptor (RXR) (fr087764 + fr087766) and estrogen receptor (ER) (fr062438 + fr62437). To con®rm that these sequences were derived from the same DNA transcript, we designed primers from each sequence and used them to amplify contiguous DNA from cDNA reverse transcribed from a pool of Fugu liver, ovary and brain RNA (MCR Geneservice) using Superscript II RNase H ± (Invitrogen). Ampli®ed bands were con®rmed by sequence analysis.
For the comprehensive comparison of the Fugu and human NR sets shown in Table 1 , each Fugu LBD sequence was identi®ed beginning with the Gly-Met linker sequence that is well conserved in the NR superfamily. Each Fugu LBD sequence was then aligned with each human LBD sequence individually using the Needleman±Wunsch algorithm as implemented in the program MVP (21) . The percent identity of each pair of nuclear receptors was calculated as i/n, where i is the number of identities in the sequence alignment and n = (n i + n j )/2, the average number of amino acids in the two sequences being aligned.
Expression analysis of Fugu NR mRNAs
Fugu brain, gill, gut, heart and ovary RNAs were ordered from MCR Geneservice. Dr Greg Elgar (UK-HGMP-RC) generously provided Fugu liver tissue. Liver RNA was prepared using the Trizol reagent (Invitrogen). RNAs were reversed transcribed using Superscript II RNase H ± (Invitrogen). Thirty cycle PCR reactions were then run with speci®c primers designed from the genomic sequence, as follows: fr078207 (PXR) 224 bp fragment from exon 5: forward, 5¢-tctttgctgtgcgcggcagc-3¢, reverse, 5¢-agagcctcacggacttcaagt-3¢; fr073157 [vitamin D receptor (VDR)] 161 bp fragment from exon 5: forward, 5¢-gacaccaagttgaatctcag-3¢, reverse, 5¢-cggctttgccaagatgattc-3¢; fr064850 (VDR) 181 bp fragment from exon 8: forward, 5¢-cctacatccggctgcaccat-3¢, reverse, 5¢-cggcagcgaggtctcc-3¢; fr070795 (LXR) 176 bp fragment from exon 4: forward, 5¢-gtggccgcagagtcaggact-3¢, reverse, 5¢-ctgaagacttcgaccatcga-3¢; fr072134 (FXR) 233 bp fragment from exon 8: forward, 5¢-cgaccttatgttaaggatc-3¢, reverse, 5¢-gtgagatctgggatgtgcag-3¢; fr082389 (FXR) 160 bp fragment from exon 9: forward, 5¢-cctgcaggcggcacactg-3¢, reverse, 5¢-ggaccctccaccacaactac-3¢. Reactions were run on a 1% agarose gel and the image was acquired using ChemiDoc with QuantityOne software (Bio-Rad). A control without Italics specify amino acids that differ from the consensus. Bold speci®es amino acids predicted to prevent fatty acid ligand binding.
reverse transcriptase was run to verify that the Fugu mRNA samples were not contaminated with genomic DNA (data not shown).
RESULTS AND DISCUSSION
General features
The F.rubripes genome contains a relatively small 365 Mb sequence. Recent analysis of the complete Fugu genome (>95% sequence coverage) (22) revealed a non-redundant set of 31 059 predicted gene loci within this sequence, similar to the number of predicted gene loci within the human genome (23, 24) . In order to identify the complete set of nuclear receptor genes within the Fugu genome, we developed a bioinformatic strategy ( Fig. 1 ) involving sequence comparison between human nuclear receptors and the 33 609 predicted peptides in the Fugu proteome. In a ®rst pass analysis, BLAST was used to scan for orthologs of the 48 human nuclear receptors in the Fugu proteome. Once putative orthologs were identi®ed, sequence alignments were constructed to ®nd conserved domains as well as novel protein family members. Using this approach we identi®ed several new family members in both the COUP transcription factor (NR2F) family as well as in the RAR-related receptor (NR1F) family. We followed up the approach using a BLAST analysis with a HMMer-based analysis. A distinguishing feature about nuclear receptors is the presence of a DBD characterized by C4-type zinc ®ngers contained in the N-terminal half of the proteins. Hidden Markov models were generated using speci®cally the DBDs and this resulted in the identi®cation of 10 new receptors not seen in the BLAST analyses. Similarly, using a second HMM that represented the LBD, we were able to identify six more receptors not seen by the BLAST analyses. Overall, we identi®ed 68 total nuclear receptors in Fugu, 20 more than are in the human NR set. Broad sequence comparison of the Fugu and human NR sets (Fig. 2) showed that all of the 68 Fugu receptors displayed signi®cant similarity to a human NR. The lack of novel subgroups within the expanded Fugu nuclear receptor set (relative to the human NR set) contrasts strikingly with a previous analogous analysis of the C.elegans NR set (8) . The C.elegans NR family underwent a dramatic proliferation and diversi®cation producing multiple novel subfamilies relative to other nonnematode genomes analyzed to date (25) . Among the high number of C.elegans receptors that did not cluster within the traditional six subfamilies seen in humans, a comparatively low degree of sequence homology with human receptors is observed (15) . Moreover, many of the novel C.elegans NR DBDs contained unique P-box regions, key determinants of DNA binding speci®city. Thus, C.elegans NRs would be predicted to bind a larger repertoire of response elements compared to vertebrate NRs. One hypothesis that has been put forward is that the diversi®ed C.elegans NRs expanded to ®ll a much broader niche in transcriptional regulation. The closer relationship between the Fugu NRs and the human NRs with respect to sequence supports the concept that proliferation of the Fugu nuclear receptor set did not occur in response to selection pressure for broader function of nuclear receptors as may have occurred in C.elegans, but is more likely to represent the result of larger scale genome-wide events. Our ®ndings were consistent with the general conclusion that most teleosts contain an excess of duplicate genes in comparison with tetrapods (9, 26) .
Presumably NR pseudogenes are present within the Fugu genome. Our bioinformatic scheme was designed to identify only receptors containing a full-length LBD (amino acid start prior to a predicted helix 1 region) and thus would not have identi®ed pseudogenes. In four cases, only partial LBD sequences were present on a single scaffold, while remaining sequence information from the same receptor subtype was found on a different scaffold (see Materials and Methods). These fragments could have represented independent pseudogene fragments or a contiguous sequence spanning two sequencing scaffolds. We showed that the latter was the case for all four of these receptors by amplifying a single cDNA fragment using 5¢ and 3¢ primers from the different scaffold sequences, thus ruling these out as pseudogene sequences. Future efforts to identify all NR sequences in the Fugu genome, including pseudogenes, should disclose more information regarding the nature of the origin of the NR gene family in teleosts. Within each NR subgroup, it would be possible to assign speci®c orthologs based solely on percent sequence identity [for example, matching a human estrogen-related receptor a (ERRa) with Fugu ERRa], but such an assignment is likely to change as the systematic nomenclature for Fugu NRs is debated. Also, the ®nal determination of nomenclature will depend on a broader set of data, including expression and other functional data. To avoid ambiguity, this manuscript identi®es each Fugu receptor by its SINFRUP number indicated as fr (22) (http://genome.jgi-psf.org/fugu3/fugu3. info.html) combined with the name of the human NR with the highest sequence similarity. The variety of non-human NR orthologs provides the basis for comparative analysis of speci®c receptors from the human nuclear receptor complement. To begin the more detailed comparison of human and Fugu NRs, we have examined in more detail multiple subgroups of current pharmacological interest.
NR1I subfamily (PXR, CAR, VDR)
The human NR1I subfamily includes the xenobiotic receptors PXR (NR1I2) and CAR (NR1I3) as well as the VDR. The PXRs are activated by a broad range of xenobiotics, steroids and bile acids, while the CARs are less promiscuous, have higher basal activities than the PXRs and are more subject to inverse activation. These functional differences effectively classify PXR and CAR as pharmacologically distinct receptors (27) . The X-ray structure of PXR revealed an unusually large and nearly spherical binding pocket that could accommodate a wide range of lipophilic ligands (28) . In contrast, modeling work suggested that the CAR ligand-binding pocket would be smaller and more selective in terms of ligand binding (27) . The hypothesized pocket expansion in PXR was thought to be caused primarily by a 50±60 amino acid insert that lies between helix 1 and helix 3 in the PXR sequence. This`helix 1±3 insert' adopts a conformation with two strands of b-sheet that effectively displace helix 6, one of the a-helices that normally line the ligand-binding pocket, thereby expanding the pocket. The helix 1±3 insert is absent in CAR, suggesting that its helix 6 should remain undisplaced, acting as a wall to constrict the ligand-binding pocket as in most other NRs. Support for this hypothesis came from functional studies of zebra®sh (Danio rerio) and chicken NR1I family members. These NRs each have comparable 45±55% sequence identity with both human PXR and human CAR, but each contains a helix 1±3 insert (27) . Functionally, the chicken and zebra®sh NR1I receptors were activated by a wide range of xenobiotics and steroids. These functional data classify these NR1I receptors as PXRs rather than CARs, in agreement with the structural classi®cation based on the presence of the helix 1±3 insert. Importantly, these studies allow us to use sequence alone to characterize newly found NR1I sequences as either PXR-like or CAR-like receptors.
With the completed Fugu sequence, we can now ask whether the Fugu has separate CAR and PXR genes or whether a single progenitor exists, presumably the representative of the separate, diverged mammalian CAR and PXR genes. When the Fugu NR set was searched for potential PXR sequences, a single CAR/PXR gene was identi®ed (fr078207). Sequence analysis showed that it displayed the hallmark structural characteristics of the PXR family members, including the helix 1±3 insert (Fig. 3) . In fact, the Fugu helix 1±3 insert displayed a higher degree of sequence similarity to the human PXR helix 1±3 insert than did the zebra®sh PXR. From these data, we predict that the Fugu receptor is the functional analog of PXR. This suggests that CAR diverged from PXR at a later point in vertebrate evolution or was lost in some or all of the teleost lines.
In mice and humans, PXR and CAR expression is highest in liver and intestine, consistent with their role in xenobiotic protection. We examined expression of the Fugu PXR in various tissue cDNA libraries using non-quantitative PCR. In contrast to the mammalian receptors, Fugu PXR was expressed in a broad range of tissues, including brain, gill, gut, heart, liver and ovary (Fig. 4) .
Two related NR1I receptors, the benzoate X receptors (BXRa and BXRb), have been identi®ed in Xenopus laevis (29, 30) . The Xenopus BXRs are specialized for the benzoate class of ligands and are pharmacologically distinct from both PXR and CAR (27, 31) . When the human NR set was analyzed, no BXR ortholog was found (8) . Until the availability of the complete Fugu sequence, it has not been possible to assess whether the BXRs are common among non-mammalian species. In our analysis, a BXR ortholog in Fugu was also not found, suggesting that this receptor could be unique to amphibians or speci®c to Xenopus. In the absence of the fully sequenced Xenopus genome, we cannot yet conclude whether amphibians have separate CAR and PXR genes in addition to the BXRs.
The VDRs are also NR1I family members, and in fact have recently been found to bind bile acids overlapping with the set that is also bound by PXR/CAR (32) . The human VDR LBD contains a helix 1±3 insert different from that of PXR. The Fugu genome contained two VDR sequences, each displaying comparable sequence similarity with the human VDR. The existence of two VDRs has been noted previously in another species of ®sh (¯ounder) (33) . As in the¯ounder, the two Fugu VDRs are more closely related to each other than to the PXRs or any other receptors.
The two VDRs in Fugu had distinct expression patterns. The receptor that was most closely related to the¯ounder VDRa, fr064850 (VDR), was expressed in all of the tissues tested, including brain, gill, gut, heart, liver and ovary (Fig. 4) . In contrast, fr073157 (VDR) displayed a much more restricted pattern of expression (Fig. 4) . Of the tissues we tested, VDRb was expressed only in the gut. Interestingly, the sole mammalian VDR is expressed in a broad range of tissues, including brain, gut, skeletal muscle and heart, liver, pancreas and immune tissues, comparable to the broad expression pattern of fr064850 (VDR). It is possible that fr073157 (VDR) has taken on a more specialized role in Fugu in the gut. 
NR1H subfamily (LXR, FXR)
The human NR1H subfamily contains the oxysterol receptors (LXRa and LXRb) and the bile acid receptor (FXR). LXRs regulate genes involved in cholesterol and lipid metabolism while FXR regulates genes involved in bile acid metabolism (5) . Within the Fugu NR set, an interesting contrast exists; the Fugu genome contains only one LXR, but two FXR sequences.
In mammals, LXRa and LXRb have contrasting expression patterns. In mouse, LXRa is expressed most predominantly in liver, macrophages, brown and white adipose tissue and intestine, while LXRb is expressed in virtually all tissues. In our analysis of the Fugu NR set, we have found that the Fugu genome contains only a single LXR gene (fr070795). Sequence analysis showed that the Fugu LXR was most closely related to the vertebrate LXRa gene. Fugu LXR displayed 75% sequence identity to the human LXRa LBD and 65% to the human LXRb LBD.
The expression pattern of Fugu LXR was assessed across a panel of tissues (Fig. 4) . Despite a higher sequence similarity to vertebrate LXRa, the pattern of expression of the Fugu LXR was more reminiscent of vertebrate LXRb. Fugu LXR was expressed in all of the tissues tested, including brain, gill, gut, heart, liver and ovary. These data may indicate that the progenitor of the mammalian LXRs may have carried out a physiological role more analogous to mammalian LXRb than LXRa. A second LXR gene with a more restricted tissue expression pattern may have arisen to function in speci®c tissues with key roles in cholesterol/lipid metabolism, such as liver, macrophages and adipose tissue. Interestingly, LXRa has been shown to be dramatically up-regulated in Figure 4 . Expression analysis. Fugu brain, gill, gut, heart and ovary RNAs were prepared from frozen tissues and subjected to PCR analysis. Speci®c primers were chosen based on exon sequences representing fr078207 (PXR), fr073157 (VDR), fr064850 (VDR), fr070795 (LXR), fr072134 (FXR) and fr082389 (FXRb), respectively. After 30 cycles of PCR, products were resolved on 1% agarose gels and visualized by ethidium bromide staining. In each case, PCR product size matched the predicted size based on sequence from the Fugu genome database (http://genome.jgi-psf.org/ fugu3/fugu3.info.html). Comparison of amino acid sequence of NR1I family members. a-Helix and b-strand residues are identi®ed with yellow and red background highlighting, respectively. The capping segment of the PXR helix 1±3 insert is highlighted in blue. The secondary structure of human PXR was determined by examination of the crystal structure (28) . For the remaining sequences, the secondary structure was predicted by the modeling analysis of Moore et al. (27) . macrophages through regulation of the LXRa gene by LXRb (34, 35) , consistent with LXRa playing a role in the ampli®cation of LXR response in certain tissues.
In contrast to the LXRs, Fugu had two FXR genes (fr072134 and fr082389) compared to the single mammalian FXR. In humans, two FXR gene sequences are present in the genome, but one sequence represents an FXR pseudogene (8) . A second FXR sequence was recently reported to exist in nonprimate vertebrates (36) and we have identi®ed the mammalian FXRb sequence in the mouse genome sequence. Fugu may represent a good model in which to contrast the function of FXRa and FXRb to gain insight into the physiological role of FXRb. In Fugu, we found that expression of the FXR (fr072134) most closely related to mammalian FXR was restricted to gut and liver (Fig. 4) . This expression pattern correlates well with the expression of mammalian FXR. In contrast, Fugu FXRb (fr082389) was expressed in a broad range of tissues (Fig. 4) . Ligand activation studies will be needed to determine whether the Fugu FXRb and the mammalian FXRb are functionally analogous.
PPARs
The human NR1C family consists of three members, PPARa, PPARd and PPARg (NR1C1, NR1C2 and NR1C3). The PPARs are receptors for endogenous and dietary fatty acids and mediate their effects on various cellular processes (37±39). Although the three PPAR subtypes are closely related and bind similar hormone response elements, each subserves a distinct role in fatty acid metabolism. PPARa agonists result in lowered triglycerides and increased high density lipoprotein cholesterol levels, while PPARg agonists are insulin sensitizers, partly due to their role in promoting adipocyte differentiation. Relatively little is known about the PPARd subtype, though it too appears to play a role in lipid homeostasis. The expression patterns of PPARa and PPARg re¯ect their different physiological functions. PPARa is expressed mainly in liver, kidney and heart, while PPARg is expressed mainly in adipose, colon and monocyte/ macrophage cells and PPARd is expressed broadly.
Fugu contained a single ortholog of the human PPARg and PPARd subtypes and two orthologs of human PPARa (fr087148 and fr074673). The expression of the four Fugu PPAR genes was examined by PCR (Fig. 4) . All four Fugu PPAR genes were broadly expressed (Fig. 4) , contrasting with the human pattern, where only PPARd is broadly expressed.
Mammalian PPARs contain four highly conserved residues that make hydrogen bonds to the acid head-group of their fatty acid ligands (40) . Table 1 lists the amino acids at these key positions (numbering relative to the human PPARg sequence) in the human receptors and their Fugu counterparts. Both Fugu PPARa orthologs (fr074373 and fr087148) have identical residues to human PPARa at these four key positions. The Fugu PPARd (fr07671) has identical residues at three of the four positions relative to human PPARd. At position 449 Fugu PPARd (fr07671) contains an Asn rather than the His residue seen in human PPARd, but this amino acid change would likely still allow binding of acidic ligands. Interestingly, the Fugu PPARg (fr054267) has two amino acid differences within these key residues that would likely prevent binding of an acidic ligand. These changes are not unique to Fugu, but are seen in the PPARg from salmon (41) as well as two other bony ®sh (¯ounder and the¯at®sh Pleuronectes platessa). Overall, these results indicate that fatty acids are not likely to activate ®sh PPARg.
Final notes
In summary, we have found striking differences between the NR sets of the Fugu and human genomes. This analysis has focused on full-length NR coding sequences predicted by in silico methods. It is possible that some of these genes, though predicted to code for full-length proteins, may turn out to be pseudogenes due to an aberrant promoter (no expression) or aberrant post-transcriptional processing (incorrect splicing). The former possibility is not likely to be true for the majority of the Fugu NR genes since all of the 10 genes whose expression was assessed by PCR were expressed.
Overall, comparison of the complete human and Fugu NR sets highlights the remarkable diversity within the NR superfamily among vertebrates. It is possible that a small number of genes may yet lie in an un®nished portion of the Fugu genome. This is unlikely due to the extent of the coverage of the Fugu genome coupled with the fact that repetitive regions with low gene content are typically the last sequences to be derived in genome sequencing projects.
The human and Fugu NR sets were very analogous in terms of NR subfamilies, but not in terms of the total number of receptors within those subfamilies. Analysis of the 68 ®sh NRs help link NRs to function, to identify key sequence motifs, to identify conserved and likely physiologically relevant mRNA variants, to understand differences between humans and pharmacological model species and to provide clues as to the potential tractability of particular receptor subgroups. Thus, the teleost genome with its expanded set of NRs provides an additional and interesting model to study both the evolution and function of the conserved vertebrate NRs. Comparisons such as these at the nucleic acid level re¯ect only one level of complexity of NR sets. The de®nition and comparison of the Fugu NR proteome (the total set of NRs resulting from differential post-transcriptional processing) will be a subject of future studies.
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